GlobeNewswire·Aug 6, 2026, 8:00 AM ET

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs.
The study demonstrated rapid oral absorption, dose-dependent systemic exposure, and comparable plasma concentrations between male & female animals.
Data indicates systemic accumulation with repeated dosing, which de-risks dose selection for the planned GLP toxicology program.
SKNY-1 is designed as an oral small-molecule therapeutic for obesity that preserves lean body mass while reducing body weight.
Preclinical studies show SKNY-1 normalizes lipids, reduces hepatic triglyceride accumulation, & attenuates compulsive feeding behavior.
The compound engages central cannabinoid pathways but shows no anxiety-related effects, distinguishing it from earlier CB1-targeting therapies.
MIRA is advancing SKNY-1 toward IND-enabling development & has determined the drug is not classified as a controlled substance by the U.S. Drug Enforcement Administration.
The Company's pipeline also includes Ketamir-2 for chemotherapy-induced peripheral neuropathy & MIRA-55 for chronic inflammatory pain.